Nose-to-brain delivery of microcarrier in the treatment of neurodegenerative diseases

HTML Full Text

Reference

1. Clementino AR, Marchi C, Pozzoli M, Bernini F, Zimetti F, Sonvico F. Anti-inflammatory properties of statin-loaded biodegradable lecithin/chitosan nanoparticles: a step toward nose-to-brain treatment of neurodegenerative diseases. Front Pharmacol. 2021;12:716380. https://doi.org/10.3389/fphar.2021.716380
2. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060). Alzheimer's Dementia. 2021;17:1966-75. https://doi.org/10.1002/alz.12362
3. Brown RC, Lockwood AH, Sonawane^ BR. Research I Mini-monoaraph neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect [Internet]. 2005;1250-6. Available from: http://dx.doi.org/iOnline https://doi.org/10.1289/ehp.7567
4. Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vladâcenco O, Roza E, et al. An overview of oxidative stress, neuroinflammation and neurodegenerative diseases. Int J Mol Sci. 2022;23(11):5938. https://doi.org/10.3390/ijms23115938
5. Zecca L, Youdim MBH, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5(11):863-73. 6. Haider MS, Mahato AK, Kotliarova A, Forster S, Böttcher B, Stahlhut P, et al. Biological activity in vitro, absorption, BBB penetration, and tolerability of nanoformulation of BT44:RET agonist with disease-modifying potential for the treatment of neurodegeneration. Biomacromolecules. 2023;24:4348-65. https://doi.org/10.1021/acs.biomac.2c00761
7. Xu J, Yang X, Ji J, Gao Y, Qiu N, Xi Y, et al. RVG-functionalized reduction sensitive micelles for the effective accumulation of doxorubicin in brain. J Nanobiotechnology. 2021;19:251. https://doi.org/10.1186/s12951-021-00997-z
8. Volkman R, Offen D. Concise review: mesenchymal stem cells in neurodegenerative diseases. Stem Cells. 2017;35(8):1867-80. https://doi.org/10.1002/stem.2651
9. Bonferoni MC, Rassu G, Gavini E, Sorrenti M, Catenacci L, Giunchedi P. Nose-to-brain delivery of antioxidants as a potential tool for the therapy of neurological diseases. Pharmaceutics. 2020;12:1-21. https://doi.org/10.3390/pharmaceutics12121246
10. Delche NA, Kheiri R, Nejad BG, Sheikhi M, Razavi MS, Rahimzadegan M, et al. Recent progress in the intranasal PLGA-based drug delivery for neurodegenerative diseases treatment. Iran J Basic Med Sci. 2023;26:1107-19.
11. Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009;9:1-5. https://doi.org/10.1186/1471-2377-9-S1-S3
12. Ale Y, Nainwal N. Progress and challenges in the diagnosis and treatment of brain cancer using nanotechnology. Mol Pharm. 2023;20(10):4893-921. https://doi.org/10.1021/acs.molpharmaceut.3c00554
13. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol. 2009;31(4): 497-511. https://doi.org/10.1007/s00281-009-0177-0
14. Akhtar A, Andleeb A, Waris TS, Bazzar M, Moradi AR, Awan NR, et al. Neurodegenerative diseases and effective drug delivery: a review of challenges and novel therapeutics. J Control Release. 2021;330: 1152-67. https://doi.org/10.1016/j.jconrel.2020.11.021
15. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1): 13-25. https://doi.org/10.1016/j.nbd.2009.07.030
16. Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133-50. https://doi.org/10.1038/nrneurol.2017.188
17. Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv. 2016;13(7):963-75. https://doi.org/10.1517/17425247.2016.1171315
18. Zhang S, Gan L, Cao F, Wang H, Gong P, Ma C, et al. The barrier and interface mechanisms of the brain barrier, and brain drug delivery. Brain Res Bull. 2022;190:69-83. https://doi.org/10.1016/j.brainresbull.2022.09.017
19. Nainwal N. Recent advances in transcranial focused ultrasound (FUS) triggered brain delivery. Curr Drug Targets. 2017;18:1225-32. https://doi.org/10.2174/1389450117666161222160025
20. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1-13. https://doi.org/10.1016/j.nbd.2003.12.016
21. Ghadiri M, Young PM, Traini D. Strategies to enhance drug absorption via nasal and pulmonary routes. Pharmaceutics. 2019;11(13):113. https://doi.org/10.3390/pharmaceutics11030113
22. Arora P Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today. 2002;7(18):967-75. https://doi.org/10.1016/S1359-6446(02)02452-2
23. Illum L. Nasal drug delivery-Possibilities, problems and solutions. J Controld Release. 2003;87: 187-98. https://doi.org/10.1016/S0168-3659(02)00363-2
24. Chaturvedi M, Kumar M, Pathak K. A review on mucoadhesive polymer used in nasal drug delivery system. J Adv Pharm Technol Res. 2011;2:215-22. https://doi.org/10.4103/2231-4040.90876
25. Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018;195:44-52. https://doi.org/10.1016/j.lfs.2017.12.025
26. Passoni A, Favagrossa M, Colombo L, Bagnati R, Gobbi M, Diomede L, et al. Efficacy of cholesterol nose-to-brain delivery for brain targeting in Huntington's Disease. ACS Chem Neurosci. 2020;11:367-72. https://doi.org/10.1021/acschemneuro.9b00581
27. Zlokovic BV. The blood-brain barrier in Health and chronic neurodegenerative disorders. Neuron. 2008;57: 178-201. https://doi.org/10.1016/j.neuron.2008.01.003
28. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64:614-28. https://doi.org/10.1016/j.addr.2011.11.002
29. Aranaz I, Paños I, Peniche C, Heras Á, Acosta N. Chitosan spray-dried microparticles for controlled delivery of venlafaxine hydrochloride. Molecules. 2017;22:1980. https://doi.org/10.3390/molecules22111980
30. Vaka SRK, Murthy SN. Enhancement of nose-brain delivery of therapeutic agents for treating neurodegenerative diseases using peppermint oil. Pharmazie. 2010;65:690-2.
31. Gänger S, Schindowski K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics. 2018 Aug 3;10(3):116. https://doi.org/10.3390/pharmaceutics10030116
32. Claus S, Weiler C, Schiewe J, Friess W. How can we bring high drug doses to the lung? Eur J Pharm Biopharm. 2014;86:1-6. https://doi.org/10.1016/j.ejpb.2013.11.005
33. Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008 Dec 10;9 Suppl 3(Suppl 3):S5. https://doi.org/10.1186/1471-2202-9-S3-S5
34. Marcello E, Chiono V. Biomaterials-enhanced intranasal delivery of drugs as a direct route for brain targeting. Int J Mol Sci. 2023 Feb 8;24(4):3390. https://doi.org/10.3390/ijms24043390
35. Ruby JJ, Pandey VP. Formulation and evaluation of olanzapine loaded chitosan nanoparticles for nose to brain targeting an in vitro and ex vivo toxicity study. J Appl Pharm Sci [Internet]. 2016 [cited 2024 Jul 23];6:034-40. https://doi.org/10.7324/JAPS.2016.60905
36. Sahil K, Akanksha M, Premjeet S, Bilandi A, Kapoor B. Microsphere: a review. IJRPC [Internet]. 2011;4(4):1184-98. Available from: www.ijrpc.com
37. Wang Z, Xiong G, Tsang WC, Schätzlein AG, Uchegbu IF. Nose-to-brain delivery. J Pharmacol Exp Therap. 2019;370:593-601. https://doi.org/10.1124/jpet.119.258152
38. Jeong SH, Jang JH, Lee YB. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Investig. 2023;53:119-52. https://doi.org/10.1007/s40005-022-00589-5
39. Fortuna A, Alves G, Serralheiro A, Sousa J, Falcão A. Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules. Eur J Pharm Biopharm. 2014;88:8-27. https://doi.org/10.1016/j.ejpb.2014.03.004
40. Patel MM, Patel BM. Crossing the blood-brain barrier: recent advances in drug delivery to the brain. CNS Drugs. 2017;31:109-33. https://doi.org/10.1007/s40263-016-0405-9
41. Pereswetoff-Morath L, Morath M. Microspheres as nasal drug delivery systems 1. Adv Drug Deliv Rev. 1998;29:185-94. https://doi.org/10.1016/S0169-409X(97)00069-0
42. Chen BK, Staff NP, Knight AM, Nesbitt JJ, Butler GW, Padley DJ, et al. A safety study on intrathecal delivery of autologous mesenchymal stromal cells in rabbits directly supporting Phase I human trials. Transfusion (Paris). 2015;55:1013-20. https://doi.org/10.1111/trf.12938
43. Nagini KSS. Formulation and evaluation of anti migraine nasal microparticles [Master's thesis]. Bangalore, India: Rajiv Gandhi University of Health Sciences; 2013.
44. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev [Internet]. 2017;97:553-622. Available from: www.prv.org https://doi.org/10.1152/physrev.00034.2015
45. Hansen JM, Charles A. Differences in treatment response between migraine with aura and migraine without aura: lessons from clinical practice and RCTs. J Headache Pain. 2019;20:96. https://doi.org/10.1186/s10194-019-1046-4
46. Assadpour S, Shiran MR, Asadi P, Akhtari J, Sahebkar A. Harnessing intranasal delivery systems of sumatriptan for the treatment of migraine. Biomed Res Int. 2022;2022:3692065. https://doi.org/10.1155/2022/3692065
47. Goadsby PJ. Migraine pathophysiology. J Head Face Pain. 2005;45:S14-25. https://doi.org/10.1111/j.1526-4610.2005.4501003.x
48. Abo El-Enin HA, Mostafa RE, Ahmed MF, Naguib IA, Abdelgawad MA, Ghoneim MM, et al. Assessment of nasal-brain-targeting efficiency of new developed mucoadhesive emulsomes encapsulating an anti-migraine drug for effective treatment of one of the major psychiatric disorders symptoms. Pharmaceutics. 2022;14:410. https://doi.org/10.3390/pharmaceutics14020410
49. Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007;47:1008-23. https://doi.org/10.1111/j.1526-4610.2007.00854.x
50. Jain SA, Chauk DS, Mahajan HS, Tekade AR, Gattani SG. Formulation and evaluation of nasal mucoadhesive microspheres of Sumatriptan succinate. J Microencapsul. 2009;26:711-21. https://doi.org/10.3109/02652040802685241
51. Gavini E, Rassu G, Ferraro L, Beggiato S, Alhalaweh A, Velaga S, et al. Influence of polymeric microcarriers on the in vivo intranasal uptake of an anti-migraine drug for brain targeting. Eur J Pharm Biopharm. 2013;83:174-83. https://doi.org/10.1016/j.ejpb.2012.10.010
52. Mistry R, Mandale D, Chauhan NN. Development, characterization and in-vitro/Ex-vivo evaluation of mucoadhesive microsphere of sumatriptan succinate for nasal delivery. Int J Pharm Res. 2021;13:430-5. https://doi.org/10.31838/ijpr/2021.13.03.060
53. Abbas Z, Marihal S. Gellan gum-based mucoadhesive microspheres of almotriptan for nasal administration: formulation optimization using factorial design, characterization, and in vitro evaluation. J Pharm Bioallied Sci. 2014;6:267-77. https://doi.org/10.4103/0975-7406.142959
54. Sharma M, Sharma N, Sharma A. Rizatriptan benzoate loaded natural polysaccharide based microspheres for nasal drug delivery system. Int J Appl Pharm. 2018;10:261-9. https://doi.org/10.22159/ijap.2018v10i5.27877
55. Jadhav S, Mishra S. The spray-dried mucoadhesive microparticles of rizatriptan with chitosan and carbopol in migraine. Egypt Pharm J. 2022;21:293-301. https://doi.org/10.4103/epj.epj_37_22
56. Liu WH, Song JL, Liu K, Chu DF, Li YX. Preparation and in vitro and in vivo release studies of huperzine a loaded microspheres for the treatment of Alzheimer's disease. J Control Release. 2005;107:417-27. https://doi.org/10.1016/j.jconrel.2005.03.025
57. Matthews KA, Xu W, Gaglioti AH, Holt JB, Croft JB, Mack D, et al. Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015-2060) in adults aged ≥65 years. Alzheimer's Dementia. 2019;15:17-24. https://doi.org/10.1016/j.jalz.2018.06.3063
58. Wen MM, El-Salamouni NS, El-Refaie WM, Hazzah HA, Ali MM, Tosi G, et al. Nanotechnology-based drug delivery systems for Alzheimer's disease management: technical, industrial, and clinical challenges. Journal of Controlled Release. 2017;245:95-107. https://doi.org/10.1016/j.jconrel.2016.11.025
59. Lista S, Dubois B, Hampel H. Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies. J Nutr Health Aging. 2015;19:154-63. https://doi.org/10.1007/s12603-014-0515-3
60. Wang J, Gu BJ, Masters CL, Wang YJ. A systemic view of Alzheimer disease - Insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol. 2017;13:612-23. https://doi.org/10.1038/nrneurol.2017.111
61. Perl DP. Neuropathology of Alzheimer's disease. Mount Sinai J Med. 2010;77:32-42. https://doi.org/10.1002/msj.20157
62. Gao Y, Almalki WH, Afzal O, Panda SK, Kazmi I, Alrobaian M, et al. Systematic development of lectin conjugated microspheres for nose-to-brain delivery of rivastigmine for the treatment of Alzheimer's disease. Biomed Pharmacother. 2021;141:111829. https://doi.org/10.1016/j.biopha.2021.111829
63. Tiozzo Fasiolo L, Manniello MD, Banella S, Napoli L, Bortolotti F, Quarta E, et al. Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: serum and brain levels in rats after nasal insufflation. Int J Pharm. 2021;605:120827. https://doi.org/10.1016/j.ijpharm.2021.120827
64. Shah BM, Misra M, Shishoo CJ, Padh H. Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization. Drug Deliv. 2015;22:918-30. https://doi.org/10.3109/10717544.2013.878857
65. Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, et al. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release. 2018;281: 139-77. https://doi.org/10.1016/j.jconrel.2018.05.011
66. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386:896-912. https://doi.org/10.1016/S0140-6736(14)61393-3
67. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol. 2000;247:3-10. https://doi.org/10.1007/PL00007758
68. Rinaldi F, Seguella L, Gigli S, Hanieh PN, Del Favero E, Cantù L, et al. inPentasomes: an innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice. J Control Release. 2019;294:17-26. https://doi.org/10.1016/j.jconrel.2018.12.007
69. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, MY Lee V, et al. Short communication aggregation of a-synuclein in lewy bodies of sporadic Parkinson's disease and dementia with lewy bodies. Am JPathol. 1998;152:879-84.
70. Dawson TM, Dawson VL. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Investig. 2003;111:145-51. https://doi.org/10.1172/JCI200317575
71. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006;7(4):306-18. https://doi.org/10.1038/nrg1831
72. Md S, Bhattmisra SK, Zeeshan F, Shahzad N, Mujtaba MA, Srikanth Meka V, et al. Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders. J Drug Deliv Sci Technol. 2018;43:295-310. https://doi.org/10.1016/j.jddst.2017.09.022
73. Dimiou S, Lopes RM, Kubajewska I, Mellor RD, Schlosser CS, Shet MS, et al. Particulate levodopa nose-to-brain delivery targets dopamine to the brain with no plasma exposure. Int J Pharm. 2022;618:121658. https://doi.org/10.1016/j.ijpharm.2022.121658
74. Hussein NR. Bioadhesive microparticles and liposomes of anti parkinsons drugs for nasal delivery [Doctoral dissertation]. Preston, UK: University of Central Lancashire; 2014.
75. Hussein N, Omer H, Ismael A, Albed Alhnan M, Elhissi A, Ahmed W. Spray-dried alginate microparticles for potential intranasal delivery of ropinirole hydrochloride: development, characterization and histopathological evaluation. Pharm Dev Technol. 2020;25:290-9. https://doi.org/10.1080/10837450.2019.1567762
76. Mantry S, Balaji A. Formulation design and characterization of ropinirole hydrochoride microsphere for intranasal delivery. Asian J Pharm Clin Res. 2017;10:195-203. https://doi.org/10.22159/ajpcr.2017.v10i7.18475
77. Jain AK, Mishra K, Thareja S. In Silico docking of anti cancerous drugs with β-cyclodextrin polymer as a prominent approach to improve the bioavailability. Anticancer Agents Med Chem [Internet]. 2020 [cited 2024 Aug 30];21:1275-83. https://doi.org/10.2174/1871520620666201013145725
78. Yang B, Dong Y, Wang F, Zhang Y. Nanoformulations to enhance the bioavailability and physiological functions of polyphenols. Molecules. 2020;25(20):4613. https://doi.org/10.3390/molecules25204613
79. Rassu G, Soddu E, Cossu M, Brundu A, Cerri G, Marchetti N, et al. Solid microparticles based on chitosan or methyl-β-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. J Control Release. 2015;201:68-77. https://doi.org/10.1016/j.jconrel.2015.01.025
80. Manta K, Papakyriakopoulou P, Nikolidaki A, Balafas E, Kostomitsopoulos N, Banella S, et al. Comparative serum and brain pharmacokinetics of quercetin after oral and nasal administration to rats as lyophilized complexes with β-cyclodextrin derivatives and their blends with Mannitol/Lecithin microparticles. Pharmaceutics. 2023;15:2036. https://doi.org/10.3390/pharmaceutics15082036
81. Nodilo LN, Ugrina I, Špoljari? D, Klari? DA, Brala CJ, Perkuši? M, et al. A dry powder platform for nose-to-brain delivery of dexamethasone: formulation development and nasal deposition studies. Pharmaceutics. 2021;13:795. https://doi.org/10.3390/pharmaceutics13060795
82. Potdar MB, Jain NK, Rathod SS, Patil KD. A Study on the nose to brain drug delivery system. Int J Pharm Sci Res [Internet]. 2022;13:569.

Article Metrics

Similar Articles

Related Search

By author names

Pandey S [PubMed] [Google Scholar ]
Nainwal N [PubMed] [Google Scholar ]
Negi T [PubMed] [Google Scholar ]
Lohar A K [PubMed] [Google Scholar ]
Kumar S [PubMed] [Google Scholar ]
Kumar S [PubMed] [Google Scholar ]
A B [PubMed] [Google Scholar ]